# Study of PBI-0451 in Healthy Subjects.

> **NCT05011812** · PHASE1 · COMPLETED · sponsor: **Pardes Biosciences, Inc.** · enrollment: 130 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** PBI-0451 Dose 1
- **DRUG:** PBI-0451 Dose 2
- **DRUG:** PBI-0451 Dose 3
- **DRUG:** PBI-0451 Dose 4
- **DRUG:** Ritonavir
- **DRUG:** Midazolam
- **DRUG:** Placebo
- **DRUG:** PBI-0451
- **DRUG:** PBI-0451 Dose 5

## Key facts

- **NCT ID:** NCT05011812
- **Lead sponsor:** Pardes Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-14
- **Primary completion:** 2022-03-26
- **Final completion:** 2022-03-26
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05011812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05011812, "Study of PBI-0451 in Healthy Subjects.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05011812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*